News

PipelineReview.com5h
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
CAMBRIDGE, MA, USA I May 01, 2025 I Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule ...
PipelineReview.com5h
Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration
Clinical trial of KH658 evaluates single suprachoroidal space administration of gene-therapy treatment for wet AMD ...